Generic oncology drug market projected to reach $39.99 billion by 2030

The global generic oncology drug market is projected to reach $39.99 billion by 2030, growing from an estimated $28.75 billion in 2025. This expansion is driven by rising cancer incidence rates and the expiration of patents for major brand-name cancer medications, which increases demand for more affordable treatment options.

Key growth drivers include the adoption of precision medicine, AI-driven drug development, and government incentives for generic manufacturing. The market is categorized into large-molecule biologics, such as trastuzumab-based therapies, and small-molecule drugs, including chemotherapy and hormone therapies.

Companies such as Pfizer, AbbVie, Novartis, Bristol Myers Squibb, and AstraZeneca are among the major players shaping the competitive landscape. Additionally, advancements in oral generic formulations are improving patient access and convenience.